MedTrace Logo

A Trial to Evaluate the Safety and and Tolerability of DBI-001 in Patients With Tinea Pedis

NCT04152226 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-06-17

Study results available
· View outcomes & findings →

Summary

This is an open-label, single-dose, dose escalating evaluation of the safety and tolerability of three dose levels of DBI-001 in patients with Tinea pedis. The purpose of the current protocol is to establish the safety and tolerability of a single application of J. lividum to the feet of patients with proven T. pedis. In addition, the effect of J. lividum on the T. pedis will also be evaluated.

Conditions

  • Tinea Pedis

Interventions

DRUG

Janthinobacterium lividum

Investigational Product

Sponsors & Collaborators

  • DermBiont, Inc.

    lead INDUSTRY

Principal Investigators

  • : Daisy Blanco, MD · Instituto Dermatologico y Cirugia de Piel

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-19
Primary Completion
2019-04-30
Completion
2019-04-30

Countries

  • Dominican Republic

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04152226 on ClinicalTrials.gov